145 related articles for article (PubMed ID: 20687172)
1. Evaluating novel agent effects in multiple-treatments meta-regression.
Salanti G; Dias S; Welton NJ; Ades AE; Golfinopoulos V; Kyrgiou M; Mauri D; Ioannidis JP
Stat Med; 2010 Oct; 29(23):2369-83. PubMed ID: 20687172
[TBL] [Abstract][Full Text] [Related]
2. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer.
Cope S; Zhang J; Saletan S; Smiechowski B; Jansen JP; Schmid P
BMC Med; 2014 Jun; 12():93. PubMed ID: 24898705
[TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
4. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
5. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis.
Golfinopoulos V; Salanti G; Pavlidis N; Ioannidis JP
Lancet Oncol; 2007 Oct; 8(10):898-911. PubMed ID: 17888735
[TBL] [Abstract][Full Text] [Related]
6. Meta-analyses of randomised trials: when the whole is more than just the sum of the parts.
Parmar MK; Stewart LA; Altman DG
Br J Cancer; 1996 Aug; 74(4):496-501. PubMed ID: 8761361
[No Abstract] [Full Text] [Related]
7. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
8. Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China.
Zhang D; Wu J; Duan X; Wang K; Ni M; Liu S; Zhang X; Zhang B; Zhao Y
Integr Cancer Ther; 2019; 18():1534735419827098. PubMed ID: 30791732
[TBL] [Abstract][Full Text] [Related]
9. Second-line systemic therapy for metastatic colorectal cancer.
Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
[TBL] [Abstract][Full Text] [Related]
10. Incorporating direct and indirect evidence using bayesian methods: an applied case study in ovarian cancer.
Griffin S; Bojke L; Main C; Palmer S
Value Health; 2006; 9(2):123-31. PubMed ID: 16626416
[TBL] [Abstract][Full Text] [Related]
11. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis.
Golfinopoulos V; Pentheroudakis G; Salanti G; Nearchou AD; Ioannidis JP; Pavlidis N
Cancer Treat Rev; 2009 Nov; 35(7):570-3. PubMed ID: 19539430
[TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
13. Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials.
Trinquart L; Abbé A; Ravaud P
PLoS One; 2012; 7(4):e35219. PubMed ID: 22536359
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
BMJ; 1991 Oct; 303(6807):884-93. PubMed ID: 1834291
[TBL] [Abstract][Full Text] [Related]
15. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
16. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
[TBL] [Abstract][Full Text] [Related]
17. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA
Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
[TBL] [Abstract][Full Text] [Related]
18. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
[TBL] [Abstract][Full Text] [Related]
19. Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.
Gay F; Jackson G; Rosiñol L; Holstein SA; Moreau P; Spada S; Davies F; Lahuerta JJ; Leleu X; Bringhen S; Evangelista A; Hulin C; Panzani U; Cairns DA; Di Raimondo F; Macro M; Liberati AM; Pawlyn C; Offidani M; Spencer A; Hájek R; Terpos E; Morgan GJ; Bladé J; Sonneveld P; San-Miguel J; McCarthy PL; Ludwig H; Boccadoro M; Mateos MV; Attal M
JAMA Oncol; 2018 Oct; 4(10):1389-1397. PubMed ID: 30098165
[TBL] [Abstract][Full Text] [Related]
20. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
